Parag Mallick - 02 Mar 2026 Form 4 Insider Report for Nautilus Biotechnology, Inc. (NAUT)

Reporting relationship: Chief Scientist, Director, 10%+ Owner
Issuer ticker: NAUT
Reported as of: 02 Mar 2026
Net transaction value: $0
SEC form: 4
Accepted by SEC: 04 Mar 2026, 17:31:31 UTC
Prior SEC filing: 12 May 2025
Source filing: View source filing
Reporting owner signature: /s/ Mathew B. Murphy, as Attorney-in-Fact

Key filing fact

Parag Mallick filed Form 4 for Nautilus Biotechnology, Inc. (NAUT) on 04 Mar 2026.

Key facts

This page summarizes Parag Mallick's Form 4 filing for Nautilus Biotechnology, Inc. (NAUT).
1 reported transaction and 1 derivative row are listed below.
Accepted by SEC: 04 Mar 2026, 17:31.

Change

Previous filing in this sequence was filed on 12 May 2025.
Current net transaction value: $0.

Research use

This tells you what this filing adds before you inspect full transaction and derivative tables.
You can trace every row back to the original SEC filing document.

Evidence

Filed on Form 4

Ownership activity is grounded in SEC Form 4 disclosures.

View source filing

Reporting Owners (1)

CIK 0001857948 Primary reporting owner

Mallick Parag

Relationship: Chief Scientist, Director, 10%+ Owner
Address: C/O NAUTILUS BIOTECHNOLOGY, INC., 2701 EASTLAKE AVENUE EAST, SEATTLE
Signature: /s/ Mathew B. Murphy, as Attorney-in-Fact
Signature date: 04 Mar 2026

Reported derivative securities

Options, warrants, convertible securities, or similar derivative positions disclosed in the filing.

NAUT transaction Derivative

Stock Option (Right to Buy)

Award

Transaction value
Shares: +280,000
Change %
Price: $0.000000^*
Shares after: 280,000
Date: 02 Mar 2026
Ownership: Direct
Underlying class: Common Stock
Underlying amount: 280,000
Exercise price: $2.32
Footnotes: F1

^* marks a reported price that did not pass the local price check.

Additional SEC filing notes

Filing notes and footnotes

Explanation of responses 1 footnote

Footnote F1

Subject to reporting person's continuous status as a "Service Provider" (as defined in the the Issuer's 2021 Equity Incentive Plan) through each vesting date, twenty-five percent (25%) of the shares subject to the Option shall vest on the one (1) year anniversary of the Vesting Commencement Date (as defined below), and one thirty-sixth (1/36th) of the remaining shares subject to the Option shall vest each month thereafter on the same day of the month as the Vesting Commencement Date (and if there is no corresponding day, on the last day of the month). The Vesting Commencement Date is January 1, 2026.